Gastroenterology Group of Naples Announces the Introduction of Axonics Sacral Neuromodulation Therapy

New Treatment Option Offers Long-Term Relief for Those Suffering from Gastrointestinal Disorders

Gastroenterology Group of Naples

Gastroenterology Group of Naples, a partner practice of United Digestive, is pleased to announce the introduction of Axonics Sacral Neuromodulation Therapy to its list of advanced treatment options for those suffering from fecal incontinence. This innovative therapy involves a minimally invasive outpatient procedure in which a device is implanted that helps to restore normal communication between the brain and bowel by gently stimulating nerves. This nerve stimulation can result in symptom improvement.
Dr. Rafael Urbina of the Gastroenterology Group of Naples explains that Axonics Therapy represents a significant advancement in the field of gastroenterology.

Axonics Therapy

“At Gastroenterology Group of Naples, we are committed to staying at the forefront of medical innovation to ensure that our patients receive the highest standard of care. Axonics Therapy represents a significant advancement in our field and heralds a new era in gastroenterology, offering patients a transformative alternative for managing certain specific gastrointestinal disorders.”

This new therapy provides an alternative solution for patients who have not found success with traditional treatments, as well as the potential for long-term relief and improved quality of life.

Dr. Rafael Urbina of the Gastroenterology Group of Naples

“This innovative approach provides hope and relief for those who have not found success with conventional treatments. Many patients with gastrointestinal disorders experience significant disruptions in their daily lives. We can now offer them a minimally invasive solution that can significantly improve their quality of life.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”